Day One Biopharmaceuticals Inc. (DAWN) Income Statement Analysis - Revenue, Earnings & Profitability Metrics - Stocknear
Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Start Trial

    Day One Biopharmaceutical...

    NASDAQ: DAWN · Real-Time Price · USD
    7.41
    -0.07 (-0.94%)
    At close: Sep 04, 2025, 3:59 PM
    7.41
    0.00%
    After-hours: Sep 04, 2025, 04:10 PM EDT

    Day One Biopharmaceuticals Income Statement

    Financials in USD. Fiscal year is January - December.

    undefined peaked at n/a in undefined and hit its lowest at n/a in undefined. Over the past five years, it has declined by undefined%.

    Fiscal Year FY 2024 FY 2023 FY 2022 FY 2021
    Period Ending Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
    Revenue
    		 131.16M n/a n/a n/a
    Cost of Revenue
    		 5.28M 383K 531K 199K
    Gross Profit
    		 125.88M -383K -531K -199K
    Operating Income
    		 -217.27M -206.06M -146.91M -72.74M
    Interest Income
    		 19.7M 17.19M 4.75M 4K
    Pretax Income
    		 -88.35M -188.92M -142.18M -72.75M
    Net Income
    		 -95.5M -188.92M -132.18M -70.44M
    Selling & General & Admin
    		 115.45M 75.54M 61.29M 29.16M
    Research & Development
    		 227.7M 130.52M 85.62M 43.58M
    Other Expenses
    		 n/a n/a -18K -15K
    Operating Expenses
    		 343.15M 206.06M 146.91M 72.74M
    Interest Expense
    		 n/a n/a 4.75M 4K
    Selling & Marketing Expenses
    		 83.9M n/a n/a n/a
    Cost & Expenses
    		 348.43M 206.06M 146.91M 72.74M
    Income Tax Expense
    		 -7.14M n/a -10.01M n/a
    Shares Outstanding (Basic)
    		 93.62M 79.77M 65.47M 61.95M
    Shares Outstanding (Diluted)
    		 93.62M 79.77M 65.47M 61.95M
    EPS (Basic)
    		 -1.02 -2.37 -2.02 -1.14
    EPS (Diluted)
    		 -1.02 -2.37 -2.02 -1.14
    EBITDA
    		 -217.27M -206.06M -141.65M -72.56M
    EBIT
    		 -88.35M -206.06M -146.91M -72.75M
    Depreciation & Amortization
    		 2.03M 383K 531K 199K

    Add to Watchlist